Encouraging private-sector innovation, making public research institutions more accountable and channelling more funds into the most promising R&D projects would help restore France’s former prowess in science and technology, a new OECD (Organization for Economic Cooperation and Development) report says.
The OECD’s Review of Innovation Policy: France recommends completing partly implemented structural changes to enable more excellence-based financing, better evaluation of public research and closer coordination between industry and the public sector. Universities should be given a greater role alongside the country’s powerful public research organizations.
Taxation holding back private sector R&D spending
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze